Medical News

RSS

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

WebMD intends to commence share repurchase program

WebMD Health Corp. announced today that it intends to commence a tender offer next week to purchase up to 3,000,000 shares of its common stock at a price per share of $50.00. The number of shares proposed to be purchased in the tender offer represents approximately 5.2% of WebMD's currently outstanding common shares. The NASDAQ Official Closing Price of WebMD's common stock on August 4, 2010 was $47.25 per share.

5 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Sunrise Senior Living reports net income of $46.3 million for second-quarter 2010

Sunrise Senior Living, Inc. today reported financial results and operating data for the second quarter of 2010.

5 Aug 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.

5 Aug 2010

Harvard Bioscience second-quarter revenues increase 43.5% to $25.9 million

Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the three and six months ended June 30, 2010.

From Harvard Bioscience 5 Aug 2010

Biovail declares quarterly dividend of US$0.095

Biovail Corporation today announced that the Company's Board of Directors has declared a quarterly cash dividend of US$0.095.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Watson Pharmaceuticals, Inc. today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009. GAAP earnings for the second quarter 2010 were $0.57 per share, compared to $0.46 per share in the prior year period.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

Cornerstone Therapeutics Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

First Edition: August 5, 2010

Today's health policy headlines examine the solvency of Medicare and Social Security; the momentum of legislation in Congress to provide states with Medicaid assistance; and the impact of Missouri's ballot challenge to health reform.

5 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

CIGNA second-quarter consolidated revenues increase to $5.4 billion

CIGNA Corporation today reported shareholders' net income of $294 million, or $1.06 per share, for the second quarter of 2010 compared with shareholders' net income of $435 million, or $1.58 per share, for the same period last year. Shareholders' net income included a loss of $0.37 per share in the second quarter of 2010 and income of $0.40 per share for the same period last year from results of the GMIB business, primarily related to interest rate movements.

5 Aug 2010

New article highlights importance of patient safety features in design of IV needleless connectors

A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.

5 Aug 2010

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

In a newly released report comparing international usage of prescription drugs, Canada ranks thirteenth among 14 countries for cancer drugs launched within the last five years. The study, conducted for the UK Secretary of State for Health, compared 14 countries for their usage of 14 categories of prescription drugs to determine whether the UK is adequately providing for the health needs of its citizens.

5 Aug 2010

Cord Blood America strengthens balance sheet by reducing financial obligations

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has had positive movement on two financial obligations that further strengthen its balance sheet.

5 Aug 2010

Stand Up To Cancer movement unveils display window in Rockefeller Plaza

Stand Up To Cancer, a groundbreaking movement that has raised more than $100 million for accelerated cancer research, today unveiled a 115-square foot display window in 10 Rockefeller Plaza, created to generate tune-in for the upcoming Stand Up To Cancer television event, set to air live for one hour, commercial-free in primetime on September 10, 2010, at 8p.m. EDT & PDT / 7 p.m. CDT.

5 Aug 2010

Medical News

Biovail second-quarter total revenues increase 23% to $238.8 million

WebMD intends to commence share repurchase program

Incyte second-quarter total revenues increase to $49.8 million

Sunrise Senior Living reports net income of $46.3 million for second-quarter 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Harvard Bioscience second-quarter revenues increase 43.5% to $25.9 million

Biovail declares quarterly dividend of US$0.095

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Micromet second-quarter 2010 total revenues increase to $6.5 million

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

First Edition: August 5, 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

CIGNA second-quarter consolidated revenues increase to $5.4 billion

New article highlights importance of patient safety features in design of IV needleless connectors

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

Cord Blood America strengthens balance sheet by reducing financial obligations

Stand Up To Cancer movement unveils display window in Rockefeller Plaza

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News